<DOC>
	<DOC>NCT02700191</DOC>
	<brief_summary>Subjects that are being treated at the Congestive Heart Failure clinic in Nazareth will be given the µ-Cor system to be added to their standard care, and randomized 1:1 to an interventional arm or a control arm.</brief_summary>
	<brief_title>Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Men or women 2090 years old. New York Heart Association (NYHA) class IIIIV heart failure Followed by the Congestive Heart Failure (CHF) clinic in Nazareth Left ventricular ejection fraction &lt;35% Requiring treatment with &gt;40mg/day of furosemide* orally or with repeated bolus or intravenous infusion of furosemide* (*or equivalent bumetanide or torasemide). Pregnancy Subjects who have received a heart transplant. Subjects who are unable or unwilling to follow the study requirements. Patients with allergies or skin sensitivities to electrode hydrogel and/or acrylic based adhesive. Patients with skin breakdown in areas on the chest where device and electrode placement is required</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>